A Review of Immune Checkpoint Blockade for the General Surgeon

被引：4

作者：

Baldwin, Xavier L. ^{[1
]}

Spanheimer, Philip M. ^{[1
]}

Downs-Canner, Stephanie ^{[2
,3
]}

机构：

[1] Univ N Carolina, Dept Surg, Sch Med, Chapel Hill, NC USA

[2] Mem Sloan Kettering Canc Ctr, Dept Surg, Breast Serv, New York, NY USA

[3] Mem Sloan Kettering Canc Ctr, Dept Surg, Breast Serv, 300 66th St, New York, NY 10065 USA

来源：

JOURNAL OF SURGICAL RESEARCH | 2023年 / 281卷

关键词：

Checkpoint inhibition; Cytotoxic T cell; Immunotherapy; T cell; SQUAMOUS-CELL CARCINOMA; ADVERSE EVENTS; COMBINED NIVOLUMAB; PD-1; BLOCKADE; PEMBROLIZUMAB; INHIBITORS; IPILIMUMAB; IMMUNOTHERAPY; ATEZOLIZUMAB; MANAGEMENT;

D O I：

10.1016/j.jss.2022.08.040

中图分类号：

R61 [外科手术学];

学科分类号：

摘要：

The immune system is a complex and interconnected system that has evolved to protect its host from foreign pathogens. CD8+ T cells are a type of immune cell that can be directly lethal to tumor cells. However, their tumor killing capabilities can be inhibited by check-point molecules. During the last decade, the development of medications that block these checkpoint molecules has revolutionized treatment for some cancer types and indications for use continue to grow. As usage of immunotherapy increases, toxicities and adverse events unique to immunotherapy are becoming more prevalent. Here, we review the commonly targeted inhibitory molecules along with their food and drug administration -approved indications in various cancer therapeutic regimens, immunotherapy-related toxicities, and how this may impact surgical planning.(c) 2022 Elsevier Inc. All rights reserved.

引用

页码：289 / 298

页数：10

共 97 条

[1]

Abbas A.K., 2018, CELL MOL IMMUNOL, V9th

[2] Immune-related ocular toxicities in solid tumor patients treated with immune checkpoint inhibitors: a systematic review [J].

Abdel-Rahman, Omar ;

Oweira, Hani ;

Petrausch, Ulf ;

Helbling, Daniel ;

Schmidt, Jan ;

Mannhart, Meinrad ;

Mehrabi, Arianeb ;

Schoeb, Othmar ;

Giryes, Anwar .

EXPERT REVIEW OF ANTICANCER THERAPY, 2017, 17 (04) :387-394

[3] FDA Approval Summary: Pembrolizumab, Atezolizumab, and Cemiplimab-rwlc as Single Agents for First-Line Treatment of Advanced/Metastatic PD-L1-High NSCLC [J].

Akinboro, Oladimeji ;

Larkins, Erin ;

Pai-Scherf, Lee H. ;

Mathieu, Luckson N. ;

Ren, Yi ;

Cheng, Joyce ;

Fiero, Mallorie H. ;

Fu, Wentao ;

Bi, Youwei ;

Kalavar, Shyam ;

Jafri, Samina ;

Mishra-Kalyani, Pallavi S. ;

Zirkelbach, Jeanne Fourie ;

Li, Hongshan ;

Zhao, Hong ;

He, Kun ;

Helms, Whitney S. ;

Chuk, Meredith K. ;

Wang, Min ;

Bulatao, Ilynn ;

Herz, Jonathan ;

Osborn, Blaire L. ;

Xu, Yuan ;

Liu, Jiang ;

Gong, Yutao ;

Sickafuse, Sharon ;

Cohen, Rebecca ;

Donoghue, Martha ;

Pazdur, Richard ;

Beaver, Julia A. ;

Singh, Harpreet .

CLINICAL CANCER RESEARCH, 2022, 28 (11) :2221-2228

[4] Neoadjuvant immune checkpoint blockade in high-risk resectable melanoma [J].

Amaria, Rodabe N. ;

Reddy, Sangeetha M. ;

Tawbi, Hussein A. ;

Davies, Michael A. ;

Ross, Merrick, I ;

Glitza, Isabella C. ;

Cormier, Janice N. ;

Lewis, Carol ;

Hwu, Wen-Jen ;

Hanna, Ehab ;

Diab, Adi ;

Wong, Michael K. ;

Royal, Richard ;

Gross, Neil ;

Weber, Randal ;

Lai, Stephen Y. ;

Ehlers, Richard ;

Blando, Jorge ;

Milton, Denai R. ;

Woodman, Scott ;

Kageyama, Robin ;

Wells, Daniel K. ;

Hwu, Patrick ;

Patel, Sapna P. ;

Lucci, Anthony ;

Hessel, Amy ;

Lee, Jeffrey E. ;

Gershenwald, Jeffrey ;

Simpson, Lauren ;

Burton, Elizabeth M. ;

Posada, Liberty ;

Haydu, Lauren ;

Wang, Linghua ;

Zhang, Shaojun ;

Lazar, Alexanderj ;

Hudgens, Courtney W. ;

Gopalakrishnan, Vancheswaran ;

Reuben, Alexandre ;

Andrews, Miles C. ;

Spencer, Christine N. ;

Prieto, Victor ;

Sharma, Padmanee ;

Allison, James ;

Tetzlaff, Michael T. ;

Wargo, Jennifer A. .

NATURE MEDICINE, 2018, 24 (11) :1649-+

[5] Pembrolizumab in Microsatellite-Instability-High Advanced Colorectal Cancer [J].

Andre, T. ;

Shiu, K-K ;

Kim, T. W. ;

Jensen, B., V ;

Jensen, L. H. ;

Punt, C. ;

Smith, D. ;

Garcia-Carbonero, R. ;

Benavides, M. ;

Gibbs, P. ;

de la Fouchardiere, C. ;

Rivera, F. ;

Elez, E. ;

Bendell, J. ;

Le, D. T. ;

Yoshino, T. ;

Van Cutsem, E. ;

Yang, P. ;

Farooqui, M. Z. H. ;

Marinello, P. ;

Diaz, L. A., Jr. .

NEW ENGLAND JOURNAL OF MEDICINE, 2020, 383 (23) :2207-2218

[6] Durvalumab after Chemoradiotherapy in Stage III Non-Small-Cell Lung Cancer [J].

Antonia, S. J. ;

Villegas, A. ;

Daniel, D. ;

Vicente, D. ;

Murakami, S. ;

Hui, R. ;

Yokoi, T. ;

Chiappori, A. ;

Lee, K. H. ;

de Wit, M. ;

Cho, B. C. ;

Bourhaba, M. ;

Quantin, X. ;

Tokito, T. ;

Mekhail, T. ;

Planchard, D. ;

Kim, Y. -C. ;

Karapetis, C. S. ;

Hiret, S. ;

Ostoros, G. ;

Kubota, K. ;

Gray, J. E. ;

Paz-Ares, L. ;

de Castro Carpeno, J. ;

Wadsworth, C. ;

Melillo, G. ;

Jiang, H. ;

Huang, Y. ;

Dennis, P. A. ;

Ozguroglu, M. .

NEW ENGLAND JOURNAL OF MEDICINE, 2017, 377 (20) :1919-1929

[7] Co-signal Molecules in T-Cell Activation [J].

Azuma, Miyuki .

CO-SIGNAL MOLECULES IN T CELL ACTIVATION: IMMUNE REGULATION IN HEALTH AND DISEASE, 2019, 1189 :3-23

[8] Adjuvant Nivolumab versus Placebo in Muscle-Invasive Urothelial Carcinoma [J].

Bajorin, D. F. ;

Witjes, J. A. ;

Gschwend, J. E. ;

Schenker, M. ;

Valderrama, B. P. ;

Tomita, Y. ;

Bamias, A. ;

Lebret, T. ;

Shariat, S. F. ;

Park, S. H. ;

Ye, D. ;

Agerbaek, M. ;

Enting, D. ;

McDermott, R. ;

Gajate, P. ;

Peer, A. ;

Milowsky, M., I ;

Nosov, A. ;

Antonio Jr, J. N. ;

Tupikowski, K. ;

Toms, L. ;

Fischer, B. S. ;

Qureshi, A. ;

Collette, S. ;

Unsal-Kacmaz, K. ;

Broughton, E. ;

Zardavas, D. ;

Koon, H. B. ;

Galsky, M. D. .

NEW ENGLAND JOURNAL OF MEDICINE, 2021, 384 (22) :2102-2114

[9] Coinhibitory Pathways in Immunotherapy for Cancer [J].

Baumeister, Susanne H. ;

Freeman, Gordon J. ;

Dranoff, Glenn ;

Sharpe, Arlene H. .

ANNUAL REVIEW OF IMMUNOLOGY, VOL 34, 2016, 34 :539-573

[10] Characterisation and management of dermatologic adverse events to agents targeting the PD-1 receptor [J].

Belum, V. R. ;

Benhuri, B. ;

Postow, M. A. ;

Hellmann, M. D. ;

Lesokhin, A. M. ;

Segal, N. H. ;

Motzer, R. J. ;

Wu, S. ;

Busam, K. J. ;

Wolchok, J. D. ;

Lacouture, M. E. .

EUROPEAN JOURNAL OF CANCER, 2016, 60 :12-25

← 1 2 3 4 5 6 7 8 9 10 →